Evaluation of Medicine Abuse Trends in Community Pharmacies: The Medicine Abuse Observatory (MAO) in a Region of Southern Europe.
community pharmacy
drug related disorders
medicine abuse
non-medical use
pharmacist intervention
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
23 07 2021
23 07 2021
Historique:
received:
07
06
2021
revised:
19
07
2021
accepted:
19
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
14
8
2021
Statut:
epublish
Résumé
The misuse of medicines is a global public health concern that needs to be taken into consideration and requires actions across all government sectors and society. The aim of this study is to identify trends of drug abuse in Catalonia, a region of Spain located in the South of Europe. For this purpose, a questionnaire-based detection tool was created and implemented in 60 community pharmacies. Out of 548 questionnaires (98.4%), 64.2% of participants were men and the highest age proportion was 25-35 years (31.4%). Potential drug abuse was the highest in urban pharmacies (84.9%). The main drug class involved were benzodiazepines (31.8%), codeine (19.3%), tramadol (7.5%), methylphenidate (5.8%), gabapentinoids (5.8%), cycloplegic drops (4.4%), z-drugs (2.6%), piracetam (2.2%), dextromethorphan (1.6%) and clomethiazole (1.1%). The majority of drugs were requested without prescription (58.6%) and through probably forged prescriptions (23.7%). Slightly less than half (49.8%) of the patients request frequently to the pharmacist, especially in rural and mountain pharmacies (73.3% and 88.5%, respectively). A small proportion (10.8%) were requested with intimidation. Pharmacists only supplied in 21.7% of the cases. This study has demonstrated the suitability of the new detection system, being a useful approach to replicate in other locations with similar needs.
Identifiants
pubmed: 34360110
pii: ijerph18157818
doi: 10.3390/ijerph18157818
pmc: PMC8345500
pii:
doi:
Substances chimiques
Codeine
UX6OWY2V7J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Drug Saf. 2009;32(10):859-73
pubmed: 19722729
Int J Neuropsychopharmacol. 2019 Apr 1;22(4):270-277
pubmed: 30722037
Health Policy. 2016 Aug;120(8):875-81
pubmed: 27344198
Prim Care. 1993 Mar;20(1):231-9
pubmed: 8464944
Pharmacoepidemiol Drug Saf. 2012 Mar;21(3):254-60
pubmed: 21953893
Pharm World Sci. 2004 Oct;26(5):282-8
pubmed: 15598070
J Addict Dis. 2013;32(1):26-38
pubmed: 23480245
Patient Educ Couns. 2006 Dec;64(1-3):136-41
pubmed: 16431072
Br J Clin Pharmacol. 2021 Apr;87(4):1668-1675
pubmed: 32503085
PLoS One. 2017 May 16;12(5):e0177645
pubmed: 28520804
Eur Addict Res. 2012;18(5):228-45
pubmed: 22572594
Res Social Adm Pharm. 2019 Aug;15(8):943-948
pubmed: 30737195
Int J Environ Res Public Health. 2020 Feb 19;17(4):
pubmed: 32092993
Drugs. 2017 Mar;77(4):403-426
pubmed: 28144823
Br J Clin Pharmacol. 2017 Aug;83(8):1791-1800
pubmed: 28239898
Gac Sanit. 2006 Dec;20 Suppl 3:52-60
pubmed: 17433201
Subst Use Misuse. 2016 Nov 9;51(13):1724-30
pubmed: 27487323
Eur J Pain. 2019 Nov;23(10):1747-1762
pubmed: 31349370
Front Psychiatry. 2021 Apr 28;12:676224
pubmed: 33995154
Eur Addict Res. 2014;20(4):174-82
pubmed: 24458222
Subst Use Misuse. 2010 Jul;45(9):1319-29
pubmed: 20509736
Health Soc Care Community. 2013 May;21(3):254-62
pubmed: 23320510
Drug Saf. 2007;30(3):265-76
pubmed: 17343432
J Am Acad Child Adolesc Psychiatry. 2020 Jan;59(1):100-112
pubmed: 31326580
J Pharm Pract. 2017 Oct;30(5):498-505
pubmed: 27402634
Subst Use Misuse. 2016 Jun 6;51(7):942-7
pubmed: 27100671
Therapie. 2015 Mar-Apr;70(2):203-21
pubmed: 25858577
Addict Sci Clin Pract. 2019 Sep 2;14(1):30
pubmed: 31474225
Subst Abuse. 2011;5:11-5
pubmed: 22879746
Drug Saf. 2020 Dec;43(12):1235-1254
pubmed: 32857333
J Addict Med. 2015 Sep-Oct;9(5):411-6
pubmed: 26291546
Am J Health Syst Pharm. 2014 Feb 1;71(3):243-6
pubmed: 24429020